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HUMAN PANCREAS GH-RELEASING FACTOR ANALOG RESTORES HIGH-AMPLITUDE GH PULSES IN CNS LESION-INDUCED GH DEFICIENCY
GLORIA SHAFFER TANNENBAUM1, ROELOF EIKELBOOM, AND NICHOLAS LING
Departments of Pediatrics, and Neurology and Neurosurgery, McGill University, Montreal, Quebec H3H 1P3, Canada,
and Laboratories for Neuroendocrinology, Salk Institute for Biological Studies, La Jolla, California 92037, USA
Transmitted by Claude Desjardins on June 21, 1983
ABSTRACT: Lesions of the ventromedial-arcuate (VMH-ARC) region of the hypothalamus result in impaired growth
accompanied by a marked suppression in spontaneous GH secretory bursts. We studied the effects of an analog
of the recently characterized human pancreas GH-releasing factor hpGRF(l-40) on GH secretory dynamics in freely-
moving chronically cannulated rats bearing electrolytic lesions of the VMH-ARC. Intravenous administration of
the hpGRF analog (hpGRFa) caused a dramatic surge of GH within 5 min; plasma GH levels rose to values as high as
2900 ng/ml and remained significantly elevated for 15-30 min post treatment. The simultaneous iv administration
of somatostatin-14 and hpGRFa resulted in a significant inhibition of the hpGRFa-induced GH release at 5 min but
not at 15 min. These results clearly demonstrate that impaired GH secretion resulting from VMH-ARC lesions can
be restored by hpGRF. The findings are promising in that hpGRF and its analogs may provide valuable agents for
the diagnosis and treatment of disorders of growth secondary to CNS dysfunction.
The most common form of GH deficiency in childhood
is thought to be due to hypothalamic dysfunction (1).
It is now well recognized that GH secretion is regula-
ted by at least two hypothalamic neurohormones - a GH
releasing factor, GRF, which has not been fully
characterized, and a GH-release inhibiting factor,
somatostatin (2). The ventromedial-arcuate (VMH-ARC)
region of the hypothalamus has been implicated as an
important neural locus for GH regulation, since elec-
trical stimulation of this brain region causes a rise
in plasma GH (3,4) whereas lesions result in growth
retardation (5,6) accompanied by a marked suppression
in spontaneous GH surges (7,8). We have demonstrated
that the latter is not due to increased release of
somatostatin (8) and have suggested that the GH
suppression is a consequence of damage to putative
GRF neurons localized in the VMH-ARC. The recent
isolation and characterization of peptides, from
human pancreas (hp) tumors (9,10), which exhibit high
GH-releasing activity and appear to be identical in
biological activity to the still unidentified hypo-
thalamic GRF (9-12) provides a useful tool to evaluate
this hypothesis. We report here that an analog of
hpGRF(l-40), [Ala34,
 S e r 3 8, Arg40]hpGRF(l-40)-0H,
successfully restores high-amplitude GH secretory
pulses in GH-deficient rats bearing lesions of VMH-ARC.
MATERIAL AND METHODS
Adult male Sprague-Dawley rats (320-360 g) were
implanted with chronic intracardiac venous cannulae
and received bilateral electrolytic lesions of the
VMH-ARC by methods previously described (8). Sham-
operated control rats were treated identically to
lesioned animals but the lesionmaker was not turned
on. After surgery the animals were placed directly
in isolation test chambers (lights on between 0600-
1800 h) with Purina rat chow and tap water available
ad libitum. Following recovery of preoperative body
weight, a 6-h basal hormonal profile was obtained
from both groups of rats. Subsequently, VMH-ARC-
lesioned rats were given 3 iv bolus injections, 90
min apart (at 1030, 1200 and 1330 h) , of the hpGRF
analog (hpGRFa). The peptide was synthesized by
solid phase techniques with a Beckman 990 peptide
synthesizer (13), and was diluted in normal saline
just prior to use to attain a concentration of
10 yg/0.3 ml. As a control, VMH-ARC-lesioned rats
1) Correspondence: Department of Endocrinology,
Montreal Children's Hospital, 2300 Tupper Street,
Montreal, Quebec H3H 1P3
received 3 iv injections, at the same time points, of
another hypothalamic releasing factor, TRH (Hoechst
Canada, Inc.), in a dose of 10 yg/0.3 ml. To study
the interaction between somatostatin and hpGRF j_n
vivo, we administered iv 208 yg somatostatin-14
(Beckman Instruments, Palo Alto, CA) simultaneously
with 10 yg hpGRFa to VMH-ARC-lesioned animals at
1030 h and compared the GH response to that observed
following administration of hpGRFa alone at 1330 h.
Blood samples were withdrawn every 15 min for periods
of 6 h (1000-1600 h) from all rats. In order to
document the rapidity of the response, a blood sample
was obtained 5 min after each injection. All blood
samples were immediately centrifuged and plasma was
separated and stored at -20 C for subsequent assay of
GH, insulin and glucose (8). At the termination of
the experiments (6-10 weeks post lesion) the animals
were killed by rapid decapitation. The extent and
location of the lesions were verified and pituitary
GH concentration was determined as previously
described (8). Student's two-tailed and paired _t
tests were used for statistical comparisons.
RESULTS
The landmarks of the VMH-ARC lesion were similar
to those delineated earlier (8). Lesions of the VMH-
ARC (n=6) caused a severe suppression in amplitude
and duration of spontaneous GH secretory episodes,
with peak GH values rarely exceeding 80 ng/ml com-
pared to >500 ng/ml in sham controls (n=5) (mean 6-h
plasma GH levels + SE: 14.2 + 2.1 vs 147.5 + 17.1
ng/ml; P_<0.001). Administration of TRH failed to
significantly alter the suppressed GH secretory
profile of VMH-ARC-lesioned rats (Figs. 1A,C). In
striking contrast, hpGRFa caused a dramatic surge of
GH within 5 min after injection and plasma GH rose to
levels as high as 2900 ng/ml (Figs. 1B,D). The mean
6-h plasma GH levels of the 2 groups of rats are shown
in Figure 2. Compared to TRH-treated controls, plasma
GH levels were significantly elevated at 5, 15 and 30
min after the first hpGRFa bolus and at 5 and 15 min
after the third bolus. However, there was no signi-
ficant difference in mean plasma GH levels between
the two groups after the 1200 h injection. There was
no significant effect of hpGRFa at any time point on
either plasma insulin or plasma glucose levels. As
shown in Figure 3, the concomitant administration of
somatostatin-14 and hpGRFa at 1030 h resulted in a
significant inhibition of the hpGRFa-induced GH
release at 5 min (17.1 + 10.2 vs 811.5 + 309.6
ng/ml; P. <0.05) but not at 15 min (525.8 + 132.9
1173
1174 RAPID COMMUNICATIONS Endo•1983
Vol 113-No 3
300
200
100
TRH
Rat 136 (3)
• • > • • •
TRH
Rat 149 (3)
• • J \ • m • * ••• • • • • >»«^~ *>» • • • • •
o
CD
360
300
200
100
hpGRFa
Rat 136 (2)
(619)H(577) (448) H (367) (546)+ + (558)
hpGRFa
Rat 149 (2)
1000 1100 1200 1300 1400
Time (hours)
1500 1600 1000 1100 1200 1300 1400
Time (hours)
1500 1600
Fig. 1. Effect of iv administration of 10 yg of either TRH (A,C) or hpGRFa (B,D) on individual, representative
six-hour GH secretory profiles in VMH-ARC-lesioned rats. Arrows indicate time of injection.
vs 500.6 + 111.8 ng/ml) post injection-.
DISCUSSION
The present findings clearly demonstrate that im-
paired GH secretion resulting from VMH-ARC lesions
can be restored by the administration of an analog
of hpGRF. High GH-releasing activity was also ob-
served with a ten-fold lower dose of hpGRFa. These
results, together with the recent immunohistochemical
detection of hpGRF-1ike immunoreactivity in both ARC
and VMH nuclei (14), provide strong support for the
view that the putative GRF neurons are localized in
the VMH-ARC region of the brain.
Possible explanations for the weak response to
hpGRFa at 1200 h may be related to pituitary GH
depletion, down-regulation of GRF receptors, inter-
ference by endogenous somatostatin, or perhaps some
combination of these factors. It is unlikely that
it is due entirely to pituitary GH depletion, since
the pituitary GH content of these VMH-ARC-lesioned
rats (662. + 119.8 yg) was sufficient to permit a
healthy response to hpGRFa, taking into account the
amount of GH released after the first bolus. It is
conceivable that the lack of effect at this time
point was due to down-regulation of GRF receptors.
In the normal rat, GH is released episodically at
3.3-h intervals, with plasma GH levels undetectable
between surges (15); thus, somatotroph GRF receptors
may be less sensitive to GRF during the intervening
trough periods. Finally, it is also possible that
endogenous levels of the inhibitory peptide
somatostatin were antagonizing the effects of hpGRFa.
It has already been demonstrated in vitro that
somatostatin inhibits hpGRF-induced GH release from
dispersed rat pituitary cells in typical non-
competitive antagonism (11,12). The present finding,
in vivo, that somatostatin-14 can inhibit hpGRFa-
induced GH release was not unexpected; however, the
data suggest that the duration of biological activity
of hpGRF may be longer than that of somatostatin-14.
The demonstration, in vivo, of potent GH-releasing
activity of an analog of hpGRF(l-40), with substi-
tutions in positions 34, 38 and 40, is consistent
with the earlier in vitro reports (9,10) indicating
that the full biological activity of hpGRF resides in
the N-terminal 28 ami no acids. The evidence presented
here in animals with hypothalamic damage is promising
in that hpGRF and its analogs may provide valuable
agents for the diagnosis and treatment of disorders
of growth secondary to CNS dysfunction, e.g., idio-
pathic hypopituitarism.
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